Best in Class!

  • ChemPubSoc Europe Logo
  • Author: Scott Williams
  • Published Date: 05 September 2011
  • Source / Publisher: ChemMedChem/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
thumbnail image: Best in Class!

Related Societies

Steroid sulfatase (STS) is a new drug target for the potential treatment of a range of hormone-dependent oncology and gynecological diseases such as breast cancer and endometriosis. A collaborative research effort led by Barry Potter, University of Bath, UK, has revealed an important class of targeted yet irreversible STS inhibitors.

Irosustat is an orally active tricyclic compound and a "first-in-class" STS inhibitor, which was developed by Potter and colleagues (see picture). It is currently undergoing human clinical trials; it shows good progress thus far and an excellent safety profile. The team generated a series of Irosustat derivatives and explored the structure–activity relationship of this clinical drug as well as its potential interactions with the target enzyme. The manner by which these compounds block STS activity is thought to involve a "suicidal" sulfamoyl group transfer to an essential amino acid within the enzyme's active site.

Although several congeners with greater potency were identified, Irosustat remains a well-established clinical drug with an overall profile that will be hard to surpass by other emerging STS inhibitors.

Article Views: 2592

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from, please contact us first for permission. more

CONNECT: on Facebook on Twitter on YouTube on LinkedIn Sign up for our free newsletter

A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH